pp-267 Tablets
Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Neoplasm, Cancer, Advanced solid tumor
Clinical stage: Phase 2
Modality: Small molecule
Mechanism & Target: Not disclosed
Route & form: Oral
Differentiation: it is a highly selective CDK7 inhibitor developed demonstrating a novel mechanism of action through cell cycle and transcriptional regulation, aiming to offer a new treatment option for patients with various types of solid tumors, particularly HR+ HER2- breast cancer and TNBC.
Manufacturer #39679
A clinical-stage biopharmaceutical company focused on oncology. Developing a small molecule therapeutic targeting oncology with global development focus. Pipeline positioned for regulatory advancement in key markets.
None